# NexGel, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/NexGel, Inc). ## Overview NEXGEL, Inc. develops and manufactures aqueous polymer hydrogel products used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates through contract manufacturing, custom and white-label products, consumer branded products, and medical devices/other, serving customers in the United States and through online and retail channels. ## Products & services • Contract manufacturing of gel rollstock • Custom and white-label gel products • Consumer branded OTC remedy products • MedaGel healthcare consumer products • Kenkoderm skincare products • Silly George beauty products • Medical device and drug-delivery development - **Contract Manufacturing** (35%) — Rollstock gel manufactured for third parties that package it into finished goods. - **Custom & White Label** (25%) — Customized gel products developed, converted, and packaged for branding partners. - **Consumer Branded Products** (35%) — Finished goods sold directly to consumers under MedaGel, Kenkoderm, and Silly George. - **Medical Devices/Other** (5%) — Development-stage medical devices and ancillary freight or other revenue items. - Contract manufacturing of gel rollstock - Custom and white-label gel products - Consumer branded OTC remedy products - MedaGel healthcare consumer products - Kenkoderm skincare products - Silly George beauty products - Medical device and drug-delivery development ## Customers NEXGEL sells to industrial and brand-owner customers that need gel rollstock or finished private-label products, as well as end consumers buying branded products online and through retail channels. Its customer base also includes strategic partners for future medical device commercialization and distributors that can bring niche products to market. - **Contract manufacturing customers** (primary) — Buy gel rollstock and package it into their own finished products. - **Custom and white-label brand partners** (primary) — Buy tailored gel formulations and finished goods for their brands. - **Direct-to-consumer shoppers** (primary) — Buy MedaGel, Kenkoderm, and Silly George products through online and retail channels. - **Medical device partners** (emerging) — Work with the company on future device and drug-delivery products. - Brand owners buying rollstock for their own finished goods - Private-label customers seeking custom gel formulations - Direct consumers purchasing OTC and skincare products - Beauty buyers for false eyelashes and eye-related products - Strategic partners for medical device commercialization ## Geography NEXGEL is a U.S.-based business with manufacturing and commercial activity centered in the United States. The company also operates through a joint venture in Granbury, Texas, and sells consumer products through online marketplaces and retail channels, which can broaden reach beyond its manufacturing footprint. - United States is the core operating and sales market - Granbury, Texas hosts the CG Converting and Packaging joint venture - Online marketplaces support consumer brand distribution - Retail and direct channels expand reach for branded products ## Strategy NEXGEL is building a multi-channel model that combines contract manufacturing, custom product development, and consumer brands. Management is also pursuing new product channels, additional branded acquisitions, and proprietary medical device and drug-delivery opportunities to broaden the revenue base and reduce reliance on any single line of business. - **Expand consumer branded products** (short-term) — Branded products can improve control over pricing, marketing, and distribution. - **Maintain and grow contract manufacturing** (short-term) — Rollstock production remains a core industrial revenue stream and supports utilization. - **Pursue acquisitions and new product channels** (medium-term) — Acquisitions and channel expansion can diversify the customer base and product mix. - **Develop proprietary medical devices** (medium-term) — Higher-value device and drug-delivery products could extend the technology platform. - Grow contract manufacturing and custom gel production - Expand consumer brands through online and retail channels - Use acquisitions to build a consumer product roll-up - Develop proprietary medical devices and drug-delivery programs - Add sales pipeline and strategic partnerships for scale ## Risks NEXGEL faces execution risk from its dependence on a small set of product lines, customer development cycles, and the need to scale new brands and devices. As a development- and acquisition-oriented company, it also carries financing, going-concern, and valuation risk, while consumer and medical products expose it to regulatory, commercialization, and demand variability. - **Going-concern and financing dependence** [high] — The company may need additional debt or equity to fund growth and acquisitions. - **Customer concentration and order volatility** [high] — Contract manufacturing and custom products can be lumpy and customer-specific. - **Commercialization risk on consumer brands** [medium] — Branded products depend on marketing, channel execution, and repeat demand. - **Medical device development risk** [medium] — New devices may not reach market or may require partner support to scale. - **Regulatory and product liability risk** [medium] — Healthcare, OTC, and cosmetic products face quality, labeling, and compliance requirements. - Dependence on a limited number of product lines and customers - Going-concern and capital-raising risk if growth funding is needed - Commercialization risk for new consumer brands and medical devices - Regulatory and product liability exposure in healthcare products - Demand volatility across contract manufacturing and consumer channels ## Accounting Key accounting judgments include revenue recognition across contract manufacturing, custom orders, and direct-to-consumer sales, where timing can differ by shipment, fulfillment, or customer acceptance. The company also relies on fair value estimates for share-based compensation and warrant liabilities, and it must assess recoverability of long-lived assets and any acquired intangibles as it expands through acquisitions. - **Revenue recognition across multiple business lines** — Affects quarterly comparability and reported mix between contract and branded sales - **Warrant liability fair value** — Can create non-cash gains or losses in other income/expense - **Share-based compensation** — Affects operating expenses and earnings volatility - **Long-lived asset and acquisition impairment** — Could lead to impairment charges if expected cash flows weaken - Revenue timing differs across rollstock, finished goods, and DTC sales - Share-based compensation uses Black-Scholes valuation estimates - Warrant liabilities are remeasured at fair value each period - Long-lived asset recoverability matters in a small, evolving business - Acquisition accounting may affect intangibles and goodwill --- *Last updated: 2026-09-24T10:46:58.164094+00:00*